Cardiff Oncology CRDF shares ended the
Cardiff Oncology CRDF shares ended the final buying and selling session 10.3% increased at $10.04. The bounce got here on a powerful quantity with a higher-than-average variety of shares altering palms within the session. This compares to the inventory’s 7.3% loss over the previous 4 weeks.
Shares of this clinical-stage biotechnology firm, with prime concentrate on oncology, surged on as traders proceed to be optimistic on its pipeline progress. Final month, it reported optimistic information from its ongoing section Ib/II examine which confirmed continued sturdy affected person response to remedy with onvansertib and progression-free survival when mixed with standard-of-care remedy in second line KRAS-mutated metastatic colorectal most cancers.
Worth and Consensus
This molecular diagnostic firm is predicted to put up quarterly lack of $0.14 per share in its upcoming report, which represents a year-over-year change of +65.9%. Revenues are anticipated to be $0.08 million, up 7.1% from the year-ago quarter.
Earnings and income development expectations actually give a very good sense of the potential energy in a inventory, however empirical analysis reveals that traits in earnings estimate revisions are strongly correlated with near-term inventory worth actions.
For Cardiff Oncology, the consensus EPS estimate for the quarter has remained unchanged during the last 30 days. And a inventory’s worth often would not hold shifting increased within the absence of any development in earnings estimate revisions. So, be sure to keep watch over CRDF going ahead to see if this current bounce can flip into extra energy down the street.
The inventory at present carries a Zacks Rank 3 (Maintain). You’ll be able to see the whole record of immediately’s Zacks Rank #1 (Robust Purchase) shares right here >>>>
Need the most recent suggestions from Zacks Funding Analysis? Right this moment, you may obtain 7 Finest Shares for the Subsequent 30 Days. Click on to get this free report
Cardiff Oncology, Inc. (CRDF): Free Inventory Evaluation Report
To learn this text on Zacks.com click on right here.
Zacks Funding Analysis
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.